Group 1 - European stock markets declined, with wind energy-related stocks leading the drop after Orsted A/S's project in the U.S. was halted [1] - The Stoxx Europe 600 index closed down 0.4%, while the UK market was closed for a holiday [1] - The French CAC 40 index fell 1.6%, with notable declines in major companies such as BNP Paribas down 3.5%, AXA SA down 3.8%, and Engie SA down 2.4% [1] Group 2 - Orsted's stock plummeted 19% to a record low, making it the worst performer in the index, following the halt of its nearly completed offshore wind project by the Trump administration [1] - Vestas Wind Systems A/S, a wind turbine manufacturer, also saw a decline of 3.5% [1] Group 3 - Keurig Dr Pepper Inc. agreed to acquire JDE Peet's NV for €15.7 billion, resulting in a 17% surge in JDE Peet's stock price [1] - Valneva SE experienced a 22% drop after its vaccine for mosquito-borne diseases was halted in the U.S. due to adverse reactions in elderly patients [1]

Group 1 - U.S. stocks experienced mixed performance, with the Dow Jones index declining over 200 points on Monday [1] - Keurig Dr Pepper Inc. shares fell sharply by 7.8% to $32.38 following the announcement of its acquisition of JDE Peet's [1] - Valneva SE shares dropped 21% to $9.19 after the FDA suspended the license for IXCHIQ [3] Group 2 - DeFi Development Corp. saw its shares dip 18% to $16.51 after announcing a $125 million offering of 4.2 million shares at $12.50 per share [3] - Venu Holding Corporation's shares fell 13.3% to $15.56 after announcing an offering of 1.7 million shares [3] - Axogen, Inc. shares declined 10.2% to $14.60 due to an FDA Major Amendment designation delaying the Avance Nerve Graft decision to December 5, 2025 [3]

Company Overview - Valneva SE is a specialty vaccine company focused on developing, manufacturing, and commercializing prophylactic vaccines for infectious diseases, addressing unmet medical needs [7] - The company has advanced multiple vaccines from early R&D to approvals and currently markets three proprietary travel vaccines [8] Recent Developments - The FDA has suspended the license for Valneva's chikungunya vaccine IXCHIQ due to four new reports of serious adverse events (SAEs) consistent with chikungunya-like illness, effective immediately [1][2] - This suspension follows the FDA's earlier decision to lift a recommended pause for individuals aged 60 and older, based on an investigation of reported SAEs [2] Financial Impact - IXCHIQ sales contributed €7.5 million to Valneva's total product sales of €91 million in the first half of 2025, with a significant portion attributed to a one-time delivery of vaccine doses for a chikungunya outbreak in La Reunion [4] Commitment to Safety and Access - Valneva is committed to maintaining high safety standards and will continue to engage with health authorities regarding IXCHIQ [3] - The CEO emphasized the company's commitment to providing access to IXCHIQ globally, especially in low-and-middle-income countries affected by chikungunya outbreaks [4] Industry Context - Chikungunya virus (CHIKV) is a mosquito-borne disease that has been identified in over 110 countries, with significant medical and economic burdens expected to grow due to climate change [5][6] - The World Health Organization (WHO) has highlighted chikungunya as a major public health problem, indicating the ongoing need for effective vaccines [6]

Core Insights - Valneva SE has received marketing authorization from Health Canada for its single-dose chikungunya vaccine, IXCHIQ, for individuals aged 12 years and older, complementing previous authorizations in Canada and Europe [1][3][10] - The vaccine demonstrates a sustained immune response for 24 months in 97% of participants, indicating its long-term efficacy [2][5] - The approval is significant as chikungunya outbreaks are increasing globally, particularly in endemic regions, highlighting the need for accessible vaccination [3][4][5] Company Overview - Valneva is a specialty vaccine company focused on developing, manufacturing, and commercializing vaccines for infectious diseases, with a strong track record in advancing vaccines from R&D to market [7] - The company currently markets three proprietary travel vaccines and is advancing multiple vaccine candidates, including those for Lyme disease and Zika virus [7] Industry Context - Chikungunya virus is a mosquito-borne disease causing severe joint pain and other debilitating symptoms, with over 3.7 million cases reported in the Americas from 2013 to 2023 [6] - The World Health Organization has identified chikungunya as a major public health issue, exacerbated by climate change and the geographical spread of mosquito vectors [6] - Valneva's partnership with CEPI aims to enhance access to IXCHIQ in low- and middle-income countries, addressing the growing public health threat posed by chikungunya [4][5]

Core Points - The FDA has lifted the recommended pause on the use of IXCHIQ for individuals aged 60 and older, following a thorough review by the European Medicines Agency (EMA) [1][2] - IXCHIQ is indicated for the prevention of disease caused by the Chikungunya Virus (CHIKV) in individuals 18 years and older at high risk of exposure [1][2] - The product's prescribing information has been updated to include reports of serious adverse events, particularly among elderly individuals with multiple underlying health conditions [2][4] Company Overview - Valneva SE is a specialty vaccine company focused on developing, manufacturing, and commercializing prophylactic vaccines for infectious diseases [7] - The company has advanced multiple vaccines from early R&D to approvals and currently markets three proprietary travel vaccines [8] - Revenues from the commercial business support the advancement of the vaccine pipeline, including candidates for Lyme disease, Zika virus, and other public health threats [9] Industry Context - Chikungunya virus (CHIKV) is a mosquito-borne disease that has caused significant outbreaks globally, with over 3.7 million cases reported in the Americas between 2013 and 2023 [6] - The World Health Organization (WHO) has identified chikungunya as a major public health problem, with the economic impact expected to grow due to climate change [6]

Company Overview - Valneva SE is a specialty vaccine company focused on developing, manufacturing, and commercializing prophylactic vaccines for infectious diseases, addressing unmet medical needs [6] - The company has advanced multiple vaccines from early R&D to approvals and currently markets three proprietary travel vaccines [7] - Revenues from its growing commercial business support the advancement of its vaccine pipeline, which includes candidates for Lyme disease, Shigella, Zika virus, and other public health threats [8] Industry Context - The chikungunya virus (CHIKV) is a mosquito-borne disease that has been identified in over 110 countries, with significant outbreaks reported since 2004 [5] - Between 2013 and 2023, more than 3.7 million chikungunya cases were reported in the Americas, indicating a substantial medical and economic burden [5] - The World Health Organization (WHO) has recognized chikungunya as a major public health problem, with the impact expected to grow due to climate change [5] Regulatory Update - The European Medicines Agency (EMA) has lifted the temporary restriction on vaccinating individuals aged 65 and above with Valneva's chikungunya vaccine IXCHIQ after a thorough safety review [1][2] - The EMA concluded that IXCHIQ should be administered when there is a significant risk of chikungunya infection, considering the benefits and risks for all age groups [2][3] - IXCHIQ was authorized in the European Union in June 2024, with a label extension granted in March 2025 for adolescents aged 12 and older [3]

Core Insights - Valneva SE has entered into an exclusive agreement with CSL Seqirus for the marketing and distribution of its three proprietary vaccines in Germany [1][2] - The agreement includes the commercialization of Valneva's chikungunya vaccine IXCHIQ® starting July 2025, and its Japanese Encephalitis vaccine IXIARO® and cholera/ETEC vaccine DUKORAL® from January 2026 [2] - This new agreement replaces a previous partnership with Bavarian Nordic, which is set to conclude at the end of December 2025 [2][3] Company Performance - Valneva's product sales reached €48.6 million in Q1 2025, with €42.8 million coming from proprietary vaccines [4] - The company anticipates product sales to grow to €170-180 million in 2025, contributing to positive cash flows for its commercial business [4] Strategic Focus - The partnership with CSL Seqirus is expected to enhance Valneva's commercial sales in Germany, leveraging CSL's strong presence in the travel vaccine market [4] - Valneva specializes in developing vaccines for infectious diseases, focusing on unmet medical needs and applying expertise across multiple vaccine modalities [5][6] Pipeline Development - Revenues from the commercial business support the advancement of Valneva's vaccine pipeline, which includes a Lyme disease vaccine candidate partnered with Pfizer and a Shigella vaccine candidate [7]

Core Points - Valneva SE, a specialty vaccine company, announced that all resolutions recommended by the Board of Directors were approved by shareholders at the Annual General Meeting held in Lyon, France [1] - The approved resolutions included the financial statements for 2024, capital increase delegations, and the appointment of Dr. Gerd Zettlmeissl to the Board for a three-year term [2] - Valneva's management confirmed the Company's full-year 2025 financial guidance during the meeting [4] Company Overview - Valneva SE develops, manufactures, and commercializes prophylactic vaccines for infectious diseases, focusing on unmet medical needs [5] - The company has advanced multiple vaccines from early R&D to approvals and currently markets three proprietary travel vaccines [6] - Valneva's commercial business revenues support the advancement of its vaccine pipeline, which includes the only Lyme disease vaccine candidate in advanced clinical development partnered with Pfizer, and other candidates against Shigella, Zika virus, and other public health threats [7] Board and Auditor Information - Dr. Gerd Zettlmeissl, a vaccine expert with over 30 years of experience, was appointed to the Board, while Mr. James Sulat was reappointed for a one-year term [2][3] - The term of Deloitte & Associés as Statutory Auditor was renewed for six years [3]

Core Insights - Valneva SE announced positive six-month antibody persistence and safety data for its Phase 2 clinical trial of the chikungunya vaccine IXCHIQ in children, supporting the initiation of a pivotal Phase 3 study in early 2026 [1][2][8] Company Overview - Valneva is a specialty vaccine company focused on developing, manufacturing, and commercializing vaccines for infectious diseases, with a strong track record in advancing multiple vaccines from early R&D to approvals [10][11] - The company currently markets three proprietary travel vaccines, including the world's first and only chikungunya vaccine, and has a pipeline that includes candidates for Lyme disease, Shigella, and Zika virus [12] Clinical Trial Results - The Phase 2 trial (VLA1553-221) involved 304 healthy children aged one to eleven years, demonstrating that a full dose of the vaccine elicited a more robust immune response compared to a half dose, with a 96.5% seroresponse rate at Day 180 [2][3][8] - The vaccine was well tolerated across all age groups tested, with no safety concerns identified, supporting the selection of the full dose for the upcoming Phase 3 trial [4][5][8] Market Context - Chikungunya poses a significant health risk, particularly in endemic areas, with Brazil reporting over one million cases from January 2019 to July 2024, and India reporting 370,000 cases during the same period [5][7] - The World Health Organization has identified chikungunya as a major public health problem, with the economic impact expected to grow due to climate change and the geographical spread of mosquito vectors [7]

Group 1 - Valneva has a total of 170,188,190 ordinary shares with a par value of €0.15 each [3] - The total number of voting rights, including suspended voting rights, is 186,313,236 [3] - A capital increase occurred without preferential subscription rights, resulting in the issuance of 2,916,666 new ordinary shares between May 10 and May 26, 2025 [3] Group 2 - Double voting rights have been granted on 236,308 ordinary shares [3] - The total number of voting rights excluding suspended voting rights is 186,188,914 [3] - The change in voting rights was recognized on May 27, 2025 [3]